Cardlytics Inc (NASDAQ:CDLX) COO Lynne Marie Laube Sells 5,740 Shares of Stock

Cardlytics Inc (NASDAQ:CDLX) COO Lynne Marie Laube sold 5,740 shares of Cardlytics stock in a transaction on Tuesday, August 20th. The shares were sold at an average price of $32.63, for a total value of $187,296.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Lynne Marie Laube also recently made the following trade(s):

  • On Thursday, August 8th, Lynne Marie Laube sold 4,200 shares of Cardlytics stock. The shares were sold at an average price of $31.06, for a total value of $130,452.00.
  • On Monday, July 22nd, Lynne Marie Laube sold 3,000 shares of Cardlytics stock. The shares were sold at an average price of $27.47, for a total value of $82,410.00.
  • On Tuesday, July 2nd, Lynne Marie Laube sold 4,200 shares of Cardlytics stock. The shares were sold at an average price of $30.00, for a total value of $126,000.00.
  • On Monday, June 24th, Lynne Marie Laube sold 1,460 shares of Cardlytics stock. The shares were sold at an average price of $23.91, for a total value of $34,908.60.
  • On Thursday, June 20th, Lynne Marie Laube sold 1,540 shares of Cardlytics stock. The shares were sold at an average price of $24.14, for a total value of $37,175.60.

NASDAQ CDLX traded down $1.00 during trading on Thursday, reaching $31.53. 505,737 shares of the company’s stock were exchanged, compared to its average volume of 345,114. The stock has a market cap of $736.44 million, a P/E ratio of -14.73 and a beta of 1.76. The company has a debt-to-equity ratio of 0.79, a quick ratio of 2.01 and a current ratio of 2.01. The company has a 50 day moving average price of $29.71 and a two-hundred day moving average price of $21.67. Cardlytics Inc has a 1 year low of $9.80 and a 1 year high of $34.64.

Cardlytics (NASDAQ:CDLX) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.35) by $0.23. The company had revenue of $48.73 million during the quarter, compared to the consensus estimate of $43.77 million. Cardlytics had a negative return on equity of 66.01% and a negative net margin of 19.60%. Cardlytics’s revenue for the quarter was up 37.0% on a year-over-year basis. During the same period in the previous year, the business earned ($0.21) EPS. Research analysts forecast that Cardlytics Inc will post -1.08 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently made changes to their positions in CDLX. BlackRock Inc. lifted its holdings in Cardlytics by 94.2% during the 2nd quarter. BlackRock Inc. now owns 903,619 shares of the company’s stock worth $23,476,000 after buying an additional 438,215 shares during the last quarter. Grantham Mayo Van Otterloo & Co. LLC acquired a new stake in shares of Cardlytics during the second quarter worth about $10,392,000. Vanguard Group Inc. increased its position in shares of Cardlytics by 46.1% during the second quarter. Vanguard Group Inc. now owns 755,132 shares of the company’s stock worth $19,618,000 after purchasing an additional 238,211 shares in the last quarter. Frontier Capital Management Co. LLC increased its position in shares of Cardlytics by 11.5% during the first quarter. Frontier Capital Management Co. LLC now owns 1,631,248 shares of the company’s stock worth $26,981,000 after purchasing an additional 168,471 shares in the last quarter. Finally, Tygh Capital Management Inc. acquired a new stake in shares of Cardlytics during the first quarter worth about $2,488,000. 75.09% of the stock is owned by institutional investors.

A number of research analysts recently issued reports on CDLX shares. Zacks Investment Research lowered Cardlytics from a “buy” rating to a “hold” rating in a report on Tuesday, July 23rd. Bank of America reiterated a “buy” rating and issued a $32.00 target price (up from $22.00) on shares of Cardlytics in a report on Wednesday, July 24th. SunTrust Banks lifted their target price on Cardlytics from $25.00 to $35.00 and gave the company a “buy” rating in a report on Friday, August 9th. JPMorgan Chase & Co. set a $43.00 price target on Cardlytics and gave the stock a “buy” rating in a report on Friday, August 9th. Finally, KeyCorp lifted their price target on Cardlytics from $25.00 to $26.00 and gave the stock an “overweight” rating in a report on Friday, May 10th. One analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $33.29.

Cardlytics Company Profile

Cardlytics, Inc operates a purchase intelligence platform in the United States and the United Kingdom. It operates in two segments, Cardlytics Direct and Other Platform Solutions. The company's platform is the Cardlytics Direct solution, a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels.

Featured Article: Growth and Income Funds

Insider Buying and Selling by Quarter for Cardlytics (NASDAQ:CDLX)

Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.